All Updates

All Updates

icon
Filter
Partnerships
Pangea Biomed, Hadassah Cancer Research Institute, and Ultima Genomics partner to enhance precision oncology for solid tumor patients
Precision Medicine
Aug 8, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Microsoft launches Face Check with Microsoft Entra Verified ID
Facial Recognition
Sep 11, 2024
Funding
3DEO raises USD 3.5 million in strategic investment from Mizuho Bank
Additive Manufacturing
Sep 6, 2024
Product updates
HyperWrite launches open-source AI model Reflection 70 billion
Generative AI Applications
Sep 5, 2024
Product updates
Google begins US rollout of AI-powered Ask Photos feature
Generative AI Applications
Sep 5, 2024
Funding
Management news
HDAX Therapeutics raises USD 3.2 million in seed funding to progress pipeline and advance preclinical candidates into trials
Precision Medicine
Sep 5, 2024
Partnerships
Sequentify partners with Dexter to expand genomic diagnostics in Romania
Precision Medicine
Sep 5, 2024
Partnerships
Elevate partners with Cultivatd for European expansion
Vertical Farming
Sep 5, 2024
Product updates
Moolec confirms harvest of its genetically engineered plant-grown products
Crop Biotech
Sep 5, 2024
Precision Medicine

Precision Medicine

Aug 8, 2024

Pangea Biomed, Hadassah Cancer Research Institute, and Ultima Genomics partner to enhance precision oncology for solid tumor patients

Partnerships

  • Pangea Biomed has partnered with the Sharett Institute of Oncology, Hadassah Cancer Research Institute, and Ultima Genomics to improve treatment predictions for solid tumor cancer using advanced genetic and transcriptomic profiling.

  • This collaboration includes comprehensive genetic profiling for patients with solid tumors at the Sharett Institute of Oncology. The data generated will be added to Pangea Biomed's AI-based ENLIGHT platform alongside RNA data from Ultima Genomics and whole-slide histopathology scans. The resulting reports, in conjunction with Hadassah's clinical analysis, are expected to enhance treatment choices for these patients. The long-term, multi-year project intends to generate a minimum of 2,000 ENLIGHT reports for patients annually.

  • Pangea Biomed is a precision oncology biotech company and the developer of ENLIGHT, an advanced multi-cancer, multi-therapy response predictor. ENLIGHT combines ML and deep RNA analysis to map tumor molecular signatures and personalize cancer care. It analyzes gene group behaviors and interactions to determine optimal treatment matches. The company's technology aims to increase the number of patients who can benefit from precision oncology treatments.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.